Tendinopathy Market Report 2026

The tendinopathy market size has grown strongly in recent years. It will grow from $13.28 billion in 2025 to $13.98 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing incidence of sports-related injuries, growing aging population, rising awareness of musculoskeletal disorders, expansion of orthopedic care services, availability of physical therapy treatment options.

The tendinopathy market size is expected to see strong growth in the next few years. It will grow to $17.01 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to increasing investments in regenerative medicine research, rising demand for minimally invasive treatments, expansion of personalized orthopedic care, growing focus on long-term pain management solutions, increasing integration of digital rehabilitation monitoring. Major trends in the forecast period include increasing adoption of regenerative treatment approaches, rising use of non-invasive therapy solutions, growing integration of imaging-guided diagnosis, expansion of personalized rehabilitation programs, enhanced focus on early condition detection.

The rising incidence of sports injuries is expected to drive growth in the tendinopathy market in the coming years. Sports injuries are physical injuries sustained during athletic activities or exercise, ranging from minor sprains and strains to severe fractures or dislocations. The increase in sports injuries is linked to intensified training and competition at younger ages, which places excessive stress on developing muscles and joints before full maturation. Such injuries can lead to tendinopathy by subjecting tendons to repetitive stress or sudden overload, resulting in microscopic tears, inflammation, and degeneration over time. For example, in November 2023, Howden Group Holdings Ltd, a UK-based insurance intermediary, reported that ankle injuries in the English Premier League surged by 170% between October 2022 and January 2023, with calf/shin injuries rising by 200% and hamstring injuries by 130%, following the FIFA World Cup Qatar 2022. Therefore, the growing incidence of sports injuries is fueling the expansion of the tendinopathy market.

Key companies in the tendinopathy market are focusing on technologically advanced products, such as bioinductive implants, to accelerate healing, promote tendon regeneration, and reduce recovery time. A bioinductive implant is a medical device that stimulates the body’s natural healing process by inducing the growth of new tendon-like tissue, improving clinical outcomes in tendon repair. For example, in July 2023, Smith+Nephew, a UK-based medical technology company, launched the REGENETEN Bioinductive Implant in India. This collagen-based device enhances tendon repair by promoting biological healing through new tissue growth at the injury site, particularly in rotator cuff repair. A key feature of the implant is its minimally invasive delivery, allowing orthopedic surgeons to reinforce tendons biologically without changing existing surgical techniques, offering a faster, safer, and more effective treatment pathway for tendinopathy patients.

In April 2023, Vander-Bend Manufacturing, Inc., a US-based medical technology company, acquired Omni Components Corporation for an undisclosed amount. Through this acquisition, Vander-Bend Manufacturing aims to expand its precision manufacturing capabilities, enhance its medical technology product offerings, and strengthen its market position by leveraging Omni Components Corporation’s expertise in complex, high-precision components. Omni Components Corporation, based in the US, specializes in medical devices for tendon surgeries.

Major companies operating in the tendinopathy market are Pfizer Inc., Johnson and Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol‑Myers Squibb Company, Novartis AG, GSK plc, Medtronic Plc, Stryker Corporation, Zimmer Biomet, Smith & Nephew plc, Arthrex, Bioventus, MIMEDX, Amniotics AB, BioPro Inc., TendoMend Ltd., Alafair Biosciences, Amniox Medical Inc., CONMED Corporation, Aevumed Inc., Parcus Medical LLC, Orthocell Ltd., CollPlant Biotechnologies Ltd., Tissue Regenix Group plc, Biorez Inc.

North America was the largest region in the tendinopathy market in 2025. The regions covered in the tendinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tendinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the tendinopathy market by increasing costs of imported medical devices, orthopedic implants, diagnostic imaging equipment, regenerative therapy materials, and rehabilitation tools used in treatment and recovery. Healthcare facilities in North America and Europe are most affected due to reliance on imported therapeutic equipment, while Asia-Pacific faces higher costs in adopting advanced treatment technologies. These tariffs are increasing treatment expenses and slowing adoption of advanced therapies. However, they are also encouraging domestic production of orthopedic devices, localized manufacturing of rehabilitation equipment, and increased investment in cost-effective treatment solutions.

The tendinopathy market research report is one of a series of new reports that provides tendinopathy market statistics, including tendinopathy industry global market size, regional shares, competitors with a tendinopathy market share, detailed tendinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the tendinopathy industry. This tendinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tendinopathy is a condition affecting the tendons, leading to pain, swelling, and decreased movement or strength. It is typically caused by repetitive stress or overuse and involves the degeneration of tendon tissue rather than acute inflammation.

The main types of tendinopathy include Achilles tendinopathy, rotator cuff tendinopathy, lateral epicondylitis (tennis elbow), patellar tendinopathy, and others. Achilles tendinopathy specifically refers to an injury of the Achilles tendon, which connects the calf muscles to the heel bone. Treatment options include therapy, medications, surgical procedures, and regenerative medicine approaches. The condition can be managed through various routes of administration, such as oral, topical, and injectable methods, and care is provided across end-users including hospitals, clinics, and ambulatory surgical centers.

The tendinopathy market consists of revenues earned by entities by providing services such as physical therapy and rehabilitation programs, pain management, arthroscopic debridement, and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The tendinopathy market also include sales of nonsteroidal anti-inflammatory drugs, creams and gels, and capsaicin creams. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.